دورية أكاديمية
أعرض في EDS

Potential Candidate Genes for Therapeutic Targeting in Chronic Myeloid Leukemia: A Pilot Study.

التفاصيل البيبلوغرافية
العنوان: Potential Candidate Genes for Therapeutic Targeting in Chronic Myeloid Leukemia: A Pilot Study.
المؤلفون: Alsamman K; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahaman Bin Faisal University, Dammam, Saudi Arabia., Alamri AM; Department of Internal Medicine, King Fahd Hospital of the University, Imam Abdulrahaman Bin Faisal University, Alkhobar, Saudi Arabia., Vatte C; Department of Clinical Biochemistry, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia., Owaidah AY; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahaman Bin Faisal University, Dammam, Saudi Arabia., Alhassan F; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahaman Bin Faisal University, Dammam, Saudi Arabia., Mubarki R; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahaman Bin Faisal University, Dammam, Saudi Arabia., El-Masry OS; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Imam Abdulrahaman Bin Faisal University, Dammam, Saudi Arabia.
المصدر: Asian Pacific journal of cancer prevention : APJCP [Asian Pac J Cancer Prev] 2023 Sep 01; Vol. 24 (9), pp. 3077-3085. Date of Electronic Publication: 2023 Sep 01.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Asian Pacific Organization for Cancer Prevention Country of Publication: Thailand NLM ID: 101130625 Publication Model: Electronic Cited Medium: Internet ISSN: 2476-762X (Electronic) Linking ISSN: 15137368 NLM ISO Abbreviation: Asian Pac J Cancer Prev Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Bangkok : Asian Pacific Organization for Cancer Prevention,
مواضيع طبية MeSH: Fusion Proteins, bcr-abl*/genetics , Fusion Proteins, bcr-abl*/metabolism , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/metabolism, Humans ; Pilot Projects ; LIM-Homeodomain Proteins ; Chronic Disease ; Protein Kinase Inhibitors/pharmacology ; Drug Resistance, Neoplasm
مستخلص: Background: Chronic myeloid leukemia (CML) is a prevalent hematological malignancy known for the presence of the Philadelphia chromosome and activation of the BCR-Abl kinase activity. Although tyrosine kinase inhibitors are widely used as the standard treatment, resistance remains a concern among certain patients. This study aimed to investigate the gene expression profile of a group of CML patients in comparison to a control group in order to identify novel candidate genes associated with the disease.
Methods: Whole transcriptome sequencing was performed, and gene expression levels were validated using quantitative real-time PCR. Additionally, single nucleotide and insertion/deletion variants were analyzed in the selected candidate genes among 10 CML patients and 4 healthy control subjects.
Results: Analysis revealed a set of differentially expressed genes, whose up- or downregulation was further confirmed by qRT-PCR. Among the upregulated genes in the patient group were ribosomal protein like (RPL) members, specifically RPL9, RPL34, RPL36A, and RPL39, while downregulation was observed in CCDC170, LDB1, and SBF1 compared to the healthy subjects. Furthermore, gene variant studies identified novel genetic changes in these candidate genes, suggesting potential clinical significance in CML.
Conclusions: This study highlights RPL9, RPL34, RPL36A, RPL39, CCDC170, LDB1, and SBF1 as potential targets in CML. Additionally, it underscores the importance of investigating these genes and their variants in larger cohort studies to assess their clinical significance in CML patients.
References: PLoS One. 2016 Oct 25;11(10):e0164804. (PMID: 27780223)
Curr Hematol Malig Rep. 2018 Dec;13(6):435-445. (PMID: 30370478)
Biotechnol J. 2014 May;9(5):652-63. (PMID: 24799381)
Front Immunol. 2022 Sep 29;13:1000396. (PMID: 36248799)
Blood Adv. 2021 Feb 23;5(4):1102-1109. (PMID: 33616651)
Clin Cancer Res. 2012 Feb 15;18(4):930-7. (PMID: 22156549)
EBioMedicine. 2017 Aug;22:28-43. (PMID: 28687497)
Front Oncol. 2021 Jul 07;11:695404. (PMID: 34307159)
Oncotarget. 2016 Dec 20;7(51):84258-84270. (PMID: 27713177)
J Taibah Univ Med Sci. 2022 Mar 10;17(5):897-903. (PMID: 36050959)
Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142)
Cancer Sci. 2021 May;112(5):1811-1821. (PMID: 33675124)
Blood. 2020 Jun 18;135(25):2252-2265. (PMID: 32181817)
Biomed Pharmacother. 2019 Dec;120:109440. (PMID: 31574377)
Breast Cancer Res. 2014 Aug 14;16(4):422. (PMID: 25116933)
Oncotarget. 2016 Dec 20;7(51):85259-85272. (PMID: 27845896)
Cancers (Basel). 2021 Nov 10;13(22):. (PMID: 34830778)
J Neurol. 2020 Sep;267(9):2705-2712. (PMID: 32444983)
Mol Cell Biol. 2020 May 28;40(12):. (PMID: 32229578)
Proc Natl Acad Sci U S A. 2014 Jun 17;111(24):8838-43. (PMID: 24876273)
Cells. 2021 Jan 10;10(1):. (PMID: 33435150)
Genome Res. 2010 Sep;20(9):1297-303. (PMID: 20644199)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
J Cell Sci. 2001 Aug;114(Pt 16):2921-7. (PMID: 11686296)
Oncol Rep. 2015 Nov;34(5):2267-72. (PMID: 26323242)
J Natl Cancer Inst. 2016 Dec 31;109(6):. (PMID: 28040796)
Cancers (Basel). 2021 Dec 14;13(24):. (PMID: 34944883)
BMC Bioinformatics. 2011 Aug 04;12:323. (PMID: 21816040)
Int J Clin Exp Pathol. 2014 Mar 15;7(4):1514-23. (PMID: 24817947)
Chin Med Sci J. 2018 Sep 20;33(3):143-151. (PMID: 30266104)
Blood. 2016 May 19;127(20):2391-405. (PMID: 27069254)
Gene. 2016 Jan 15;576(1 Pt 3):421-8. (PMID: 26526135)
Nat Med. 2017 Jun;23(6):692-702. (PMID: 28504724)
Aging (Albany NY). 2020 Dec 3;13(1):1332-1356. (PMID: 33291081)
FASEB J. 2021 Apr;35(4):e21322. (PMID: 33710681)
Biomolecules. 2019 May 24;9(5):. (PMID: 31137733)
Urol Oncol. 2022 May;40(5):197.e1-197.e9. (PMID: 35382986)
Int J Oncol. 2016 Nov;49(5):1953-1962. (PMID: 27633352)
فهرسة مساهمة: Keywords: CCDC170; CML; LDB1; RPL; SBF1
المشرفين على المادة: EC 2.7.10.2 (Fusion Proteins, bcr-abl)
0 (LIM-Homeodomain Proteins)
0 (Protein Kinase Inhibitors)
تواريخ الأحداث: Date Created: 20230929 Date Completed: 20231002 Latest Revision: 20240105
رمز التحديث: 20240105
مُعرف محوري في PubMed: PMC10762750
DOI: 10.31557/APJCP.2023.24.9.3077
PMID: 37774059
قاعدة البيانات: MEDLINE
الوصف
تدمد:2476-762X
DOI:10.31557/APJCP.2023.24.9.3077